Pfizer to replace migraine drug packaging over child safety concerns
Send a link to a friend
[March 17, 2023]
(Reuters) -Pfizer Inc said on Thursday it was working on a new
child-proof packaging for its migraine drug, Nurtec ODT, after safety
concerns led to a recall alert from the U.S. Consumer Product Safety
Commission (CPSC).
Consumers should immediately secure the recalled product out of the
sight and reach of children and contact Pfizer for a free
child-resistant pouch to store it, the CPSC said.
The CPSC defines recalls as any repair, replacement, refund, or warning.
Pfizer said it was developing a new packaging for the drug acquired
through its $11.6 billion buyout of Biohaven Pharmaceutical Holding in
2022.
As an interim measure, the company has instructed pharmacists to place
the drug packet in a child-resistant vial before dispensing it to
patients.
"Patients should rest assured that there are no quality or safety issues
nor health risks when they take the medicine as prescribed for its
approved use," the company said in a statement.
[to top of second column]
|
![](../images/031723PIX/health69.jpg)
The Pfizer logo is pictured on their
headquarters building in the Manhattan borough of New York City, New
York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo
![](http://archives.lincolndailynews.com/2023/Mar/17/images/ads/current/xamis_lda_ANIMAL_2023.png) The orally disintegrating tablets
are used for the treatment of acute migraine and as preventive
treatment for episodic migraine in adults.
(Reporting by Raghav Mahobe and Aditya Samal in BengaluruEditing by
Vinay Dwivedi)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |